News

April 18, 2022

April 18 is European Patients’ Rights Day (EPRD).

The European Charter of Patients’ Rights proclaims 14 rights that aim to guarantee “a high level of protection of human health” and to ensure the provision of high quality of health services in European countries, in particular during the Covid pandemic.

More specifically, this charter proclaims:

• The right to information (“access to all that scientific research and technological innovation makes available”),
• The right to consent for any procedure or treatment, but also for participation in clinical trials,
• The right to innovation (“right of access to innovative procedures, including diagnostic procedures”), which implies the right of access to treatments or medical devices assessed in clinical trials.

The European Clinical Trials Regulation (Regulation (EU) No 536/2014) also aims to guarantee the rights of patients, and all of the medical writers at Synergy Pharm/Santé Active Edition are committed to ensuring that information relating to compliance with ethical standards and good clinical practice is clearly stated in publications reporting the results of clinical trials.

Our regulatory medical writing team also provides other medical writing services for clinical projects, including the information notes and Informed Consent Forms (ICFs) that should be provided to patients before their inclusion in a clinical study, as well as other study-related documents: Clinical Study Protocols (CSPs), Investigator’s Brochures (IBs), Investigational Medicinal Product Dossiers (IMPDs) for Clinical Trial Authorizations (CTAs), Clinical Study Reports (CSRs), etc.

March 14, 2022

On the occasion of the national “Week Against Cancer” campaign in France, it is important to highlight research efforts aimed at reducing the side effects associated with cancer treatments.

Indeed, while the range of treatments available – used alone or in combination – are effective against cancer, they can have many side effects, particularly on the skin. Xerosis is one of the most frequent side effects of cancer therapy and requires appropriate management to help maintain patient quality of life and prevent potential interruptions to cancer treatment.

A recent multicenter, real-world, phase IV study demonstrated the benefits of using an emollient containing a postbiotic in the management of 319 patients with xerosis associated with a range of cancer treatments (chemotherapy, targeted therapy, radiotherapy, hormonotherapy and immunotherapy).

A previous multicentre, real-world, phase IV study had already demonstrated the effectiveness of this emollient for the management of xerosis in 5,910 patients with a range of skin conditions (atopic dermatitis, senile xerosis, ichthyosis, psoriasis, prurigo nodularis of Hyde etc.) and underlying systemic conditions (diabetes mellitus, thyroid disease, renal insufficiency, etc.).

These two articles, published in Dermatology and Therapy and written by our medical writing team, can be found here:

• https://link.springer.com/article/10.1007/s13555-022-00685-2
• https://link.springer.com/article/10.1007/s13555-020-00415-6

March 9, 2022

Next week (14^th – 20^th of March) is the 24^th Brain Awareness Week (BAW), “a global campaign to foster public enthusiasm and support for brain science” (https://www.brainawareness.org/about/).

There are many events taking place across the world, and several activities are also being proposed to help you get involved in the campaign.

In France, the “Société des Neurosciences” is hosting an extensive program, with replays of a range of conferences also being made available.

Many of the topics covered are related to themes* that our medical writing team has addressed in the form of articles and/or sketchnotes for the general public in collaboration with the “Observatoire B2V des Mémoires” (B2V Memory Observatory): https://www.synpharm.com/en/sketchnote/

*Learning, Brain and Artificial Intelligence, Brain and New Technologies, Brain and Society, Brain and Sport, Sleep, The 5 senses, Emotions, Memory, The Sick Brain.

February 28, 2022

By definition, a rare disease has a prevalence of 1/2,000. But rare diseases are numerous and would affect more than 3 million people in France, more than 300 million in the world!

Most of these diseases have no treatment. Nevertheless, many actors are mobilized in the fight against rare diseases to improve the diagnosis, care and follow-up of the patients concerned; research in this area also allows significant medical advances.

In 2021, we again had the opportunity to put our medical writing skills at the service of several rare diseases, including craniofacial microsomia, cystic fibrosis, and inherited epidermolysis bullosa.

January 25, 2022

Synergy Pharm feels particularly concerned about Neglected Tropical Diseases (NTDs) and keeps you informed about the activities of the WHO.

On Sunday 30 January 2022, the WHO will celebrate the World Neglected Tropical Diseases Day (WNTDD). The WHO activities aim to mobilize the world to defeat NTD (https://www.who.int/campaigns/world-ntd-day/world-ntd-day-2022).

December 2, 2021

On 31 January 2022, Clinical Trials Regulation (Regulation (EU) No 536/2014) will go live, repealing EU Clinical Directive (EC No 2001/20/EC) and changing how Clinical Trials are conducted in the European Union (EU).

November 9, 2021

Although hair disorders are common, their management still represents a major clinical challenge in dermatological practice despite the emergence of new diagnostic tools and new treatment options.

October 29, 2021

Today is World Psoriasis Day. It is a great opportunity to share a review of the literature on this chronic skin pathology.

October 12, 2021

October is Breast Cancer Screening Awareness Month.

More than 355,000 women were newly diagnosed with breast cancer, and nearly 92,000 women died from the disease across the EU-27 in 2020.

September 30, 2021

International Translation Day is a great opportunity to talk about the translation service offered by our medical communication agency.